New Tricks for an Old Drug

Join Our Community of Science Lovers!

To date, the drug sulindac has seen two primary uses: treating such inflammatory diseases as rheumatoid arthritis and preventing the growth of potentially precancerous colon polyps. But in today¿s Proceedings of the National Academy of Sciences, researchers from New York report yet another indication: sulindac may help prevent the narrowing of arteries after angioplasty¿a procedure that involves widening blood vessels blocked by atherosclerosis using a tiny balloon or stent. Angioplasty works well in the short term, but it can injure the artery wall. In these cases, the injury probably leads to an inflammatory response, which in turn stimulates the growth of smooth muscle cells that narrow the vessel all over again.

To test sulindac's effects in mice, the authors injured an artery in the upper leg of the animals using a procedure similar to angioplasty and then gave sulindac to some animals, aspirin to others and no treatment to a third group. After four weeks, they found that mice receiving sulindac showed considerably less thickening of their artery walls than the others. The effect was even more pronounced in mice that, as the result of a genetic defect, had very high blood cholesterol levels. (Most patients who undergo angioplasty also have high blood cholesterol levels.) These mice, when untreated, showed more than twice as much wall thickening as normal mice. Yet after treatment with sulindac, their arterial walls were the same size as those of normal mice receiving the drug.

The reasearchers do not know why sulindac worked and aspirin did not. Both are nonsteroid, anti-inflammatory agents, known to inhibit an enzyme called cyclooxygenase. The only guess so far is that sulindac might have additional effects, including inhibiting macrophages, or the growth of smooth muscles cells or endothelial cells. Whatever the mechanism, sulindac might help people who have undergone angioplasty avoid having their arteries clog up again.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


 

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe